Batzloff Michael R, Yan Huaru, Davies Mark R, Hartas Jon, Lowell George H, White Gregory, Burt David S, Leanderson Tomas, Good Michael F
The Cooperative Research Centre for Vaccine Technology and the Australian Centre for International Tropical Health and Nutrition, The Queensland Institute of Medical Research, Brisbane, Australia.
J Infect Dis. 2005 Oct 15;192(8):1450-5. doi: 10.1086/466528. Epub 2005 Sep 9.
Infection with group A streptococcus (GAS) may result in a number of clinical conditions, including the potentially life-threatening postinfectious sequelae of rheumatic fever and rheumatic heart disease. As part of the search for a vaccine to prevent GAS infection, a conformationally constrained and minimally conserved peptide, J14, from the M protein of GAS has been defined. In the present study, J14 was formulated with bacterial outer membrane proteins (proteosomes) and then intranasally administered to outbred mice without additional adjuvant. Such immunization led to high titers of J14-specific serum immunoglobulin (Ig) G and mucosal IgA. After upper respiratory tract GAS challenge, immunized mice demonstrated increased survival and reduced GAS colonization of the throat.
感染A组链球菌（GAS）可能导致多种临床病症，包括风湿热和风湿性心脏病等具有潜在生命威胁的感染后后遗症。作为寻找预防GAS感染疫苗的一部分，已确定了一种来自GAS M蛋白的构象受限且保守性最低的肽J14。在本研究中，J14与细菌外膜蛋白（蛋白酶体）配制在一起，然后在不添加额外佐剂的情况下经鼻内给予远交群小鼠。这种免疫导致J14特异性血清免疫球蛋白（Ig）G和粘膜IgA的高滴度产生。在上呼吸道受到GAS攻击后，免疫小鼠的存活率提高，喉咙处的GAS定植减少。
